Evaluating speech patterns to understand Alzheimer's disease
Connected Language and Speech Along the Spectrum of ADRD: Digital Assessment and Monitoring
University of Wisconsin, Madison · NCT06230783
This study is testing if changes in how people speak can help spot early signs of Alzheimer's disease in those at higher risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 165 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | University of Wisconsin, Madison (other) |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT06230783 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate changes in speech as a measure of cognition in individuals at increased risk of Alzheimer's disease and related dementias. Participants will use an iPad to record their speech and complete surveys at home over a period of three years. The study leverages digital technology to gather information on early cognitive changes associated with Alzheimer's disease, focusing on noninvasive and accessible assessment methods. Researchers will analyze speech metrics to enhance the sensitivity and specificity of cognitive assessments.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 40-80 who are enrolled in the Wisconsin Alzheimer's Disease Research Center or the Wisconsin Registry for Alzheimer's Prevention and are either cognitively unimpaired or diagnosed with Mild Cognitive Impairment.
Not a fit: Patients with a diagnosis of dementia or major neurological conditions, as well as those with speech disorders, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new, low-burden method for early detection and monitoring of Alzheimer's disease.
How similar studies have performed: Other studies have shown promise in using speech analysis for cognitive assessment, indicating that this approach may be viable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Must be enrolled in the Wisconsin Alzheimer's Disease Research Center (W-ADRC) Clinical Core or IMPACT studies, or in the Wisconsin Registry for Alzheimer's Prevention (WRAP) * Cognitively unimpaired or have a diagnosis of Mild Cognitive Impairment (MCI) * Ages 40-80 years * Completion of a W-ADRC or WRAP study visit within the past or upcoming 12 months * Have provided W-ADRC or WRAP with blood plasma Alzheimer's Disease Exclusion Criteria: * Not actively enrolled in W-ADRC or WRAP * Diagnosis of dementia * Impaired capacity or unwilling to consent * Major neurological conditions * Speech disorders
Where this trial is running
Madison, Wisconsin
- University of Wisconsin — Madison, Wisconsin, United States (RECRUITING)
Study contacts
- Principal investigator: Kimberly D Mueller, PhD, CCC-SLP — University of Wisconsin, Madison
- Study coordinator: Lizzy Sielaff
- Email: esielaff@wisc.edu
- Phone: 608-264-1019
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Wisconsin Alzheimer's Disease Research Center, Wisconsin Registry for Alzheimer's Prevention